ASSESSMENT OF CARDONAT EFFICIENCY IN CARDIOMYOPATHY TREATMENT AFTER PHYSICAL OVERLOAD IN ATHLETES

  • V. Klapchuk Zaporizhzhia National Technical University, Zaporizhzhia, Ukraine
  • V. Bezugla Ukrainian Medical Center of Sports Medicine of the MoH of Ukraine, Kyiv, Ukraine
  • Yu. Vinnichuk National University of Physical Education and Sports of Ukraine, Kyiv, Ukraine
Keywords: sport, Cardonat, cardiovascular system of athletes, cardiomyopathy, chronic overstrain, electrocardiography, echocardiography, physical capacity

Abstract

Introduction. Modern sport of higher achievements is inextricably linked with constant physical activity of high intensity, which ultimately leads to the formation of overstrain phenomena in the first place of the cardiovascular system. The problems of drug correction remain virtually unresolved which emphasizes the urgency of the creation and clinical implementation of non-prohibited metabolic drugs aimed for the athletes of high qualification.

The purpose. Determination of the role of Cardonat in the cardiomyopathy, treatment caused by chronic physical overload (CMPCPO) in athletes.

Materials and methods. The study involved 48 athletes (representatives of cyclic sports) with a diagnosis of CMPCPO who were randomized into 2 equivalent (n = 24) groups: the main group and the control group. Athletes of both groups from the moment of diagnosis reduced. The volume and intensity of training loads was reduced in athletes of both groups by 75%. Control group participants received only basic therapy (Panangin, Triovite in therapeutic doses) and placebo (capsule with starch). Athletes of the main group in addition to basic therapy used Cardonat, one capsule three times a day for 4 weeks. Comprehensive study of athletes before and after the course of treatment included the determination of anthropometric data, anamnesis, physical examination, blood pressure measurements, 12-channel electrocardiography (ECG), echocardiography (Echo) in a state of relative rest, determination of overall physical disability

Results. The results of a study of the effectiveness of Сardonat treatment in representatives of cyclic sports with cardiomyopathy due to chronic physical overload are presented. It was shown that the addition of the drug to the complex therapy of this category of athletes is accompanied by positive clinical and instrumental changes in the activity of the cardiovascular system. Consequently, under the influence of Cardonat, the percentage of athletes who had complaints of heart pain, heart palpitations, manifestations of asthenic syndrome, significantly decreased. Frequency of recording systolic murmur in the apex of the heart significantly reduced in 38% of the athletes in auscultation. According to the ECG in the dynamics of treatment, there is a significant improvement in the repolarization processes of the left ventricle (normalization of the ST segment and T-wave), a decrease of rhythm disturbance and athletes percentage with a tendency to tachycardia. On echocardiography more significant reverse remodeling of the left ventricle, regression of myocardial hypertrophy and improvement of diastolic function were observed compared with the results of the control group. According to the PWC170 test the level of physical performance is significantly increased.

Conclusions. The additional use of Cardonat in therapy is safe, expedient, pathogenetically justified and can be considered as an important reserve for providing pharmacological assistance to athletes with CMPCPO.

The use of Cardonat in complex therapy is safe, expedient, pathogenetically justified and can be considered as an important reserve for providing pharmacological assistance to athletes with CMPCPO.

References

1. Belotserkovsky ZB, Lyubina BG. Serdechnaya deyatel'nost' i funkcional'naya podgotovlennost' u sportsmenov. Norma i atipichnye izmeneniya [Cardiac activity and functional preparedness of athletes. Norm and atypical changes]. Moskva: Sov. sport, 2012. 548 p.
2. Corrado D, Calore C, Zorzi A, Migliore F. Improving the interpretation of the athlete’s electrocardiogram. Eur Heart J. 2013;34(47):3606 – 3609. doi: 10.1093/eurheartj/eht458
3. Mont L, Pelliccia A, Sharma S, Biffi A et al. Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: Position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE. Europace. 2017;19:139–163. doi: 10.1093/europace/euw243
4. Drezner JA, Ackerman MJ, Anderson J, Ashley E, Asplund CA, Baggish AL et al. Electrocardiographic interpretation in athletes: the ‘Seattle Criteria’. Br. J. Sports Med. 2013;47(3):122 –124. doi: 10.1136/bjsports-2012-092067
5. Mykhaliuk YeL, Malakhova SM, Cherepok OO, Smyrnova OL. Fizychna reabilitatsiia ta sportyvna medytsyna v stomatolohii [Physical rehabilitation and sports medicine in dentistry]. Zaporizhzhia: ZDMU, 2011. 160 p.
6. World anti-doping code 2015 with 2018 amendments Retrieved from: hhttps://www.wada-ama.org/sites/default/files/resources/files/wada_anti-doping_code_2018_english_final.pdf
7. Frolova TV, Okhapkina OV, Tereshchenkova II, Berus AV. [The expediency of using and evaluating the effectiveness of Cardonate in the treatment of dysplastic-dependent pathology in children with fibrillogenic disorder]. Liky Ukrainy. 2010;2(139):73–76.
8. Yakovleva OA, Zhamba AO. [Cardioprotector effects of сardonate in patients with asthma]. Krovoobih ta hemostaz. 2009;1-2:21–25.
9. Gunina LM, Bezuglaya VV, Bagauri OV. [The use of Cardonate to increase tolerance to physical activity]. Liky Ukrainy. 2013;3(169):64-67.
10. Sviridova NK. [Why carnitine deficiency is relevant in the treatment of patients with neurological disorders]. East European Journal of Neurology. 2015;1(1):33-38.
11. Gunina LM, Golovashchenko RV. [The role of metabolic cardonate preparation in maintaining the balance of physical preparedness and homeostat in qualified runners at medium distances]. Aktualni problemy fizychnoi kultury i sportu. 2011; 20(1):19 – 24.
12. Mihalyuk EL, Syvolap VV, Tkalich IV, Atamanyuk SI. [Functional tests in sports medicine: positive and negative aspects of their conduct]. Aktualni pytannia farmatsevtychnoi i medychnoi nauky ta praktyky. 2010;1:93-96.
13. Sharma S, Drezner JA, Baggish A, Papadakis M et al. International recommendations for electrocardiographic interpretation in athletes. J. Am. Col.l Cardiol. 2017;69(8):1057-1075. doi: 10.1016/j.jacc.2017.01.015
14. Lang RM, Badano LP, Mor-Avi V, Afilalo J Armstrong A et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur. Heart J. Cardiovasc. Imaging. 2015;16(3):233-270. doi: 10.1093/ehjci/jev014
15. Karpman VL, Hrushchev SV, Borisova YU. A. Serdce i rabotosposobnost' sportsmena [Heart and performance athlete]. Moskva: Fizkul'tura i sport, 1978. 120 p.
16. Lang TA, Sesik M. Kak opisyvat' statistiku v medicine: rukovodstvo dlya avtorov, redaktorov i recenzentov [How to describe statistics in medicine: a guide for authors, editors and reviewers]. Moskva: Prakticheskaya medicina, 2011. 480 p.
17. Ovcharenko LK, Tkachenko LA, Yarmola TI, Mohnachev OV, Tsyganenko IV. [The effectiveness of the drug in clinical practice “Steatel” in patients with dilated cardiomyopathy]. Bulletin of problems biology and medicine. 2015;4(121):171-174.
18. Herrera MD, Bueno R, Sotomayor A, Pérez-Guerrero C, Vázquez CM, Marhuenda E. Endothelium-dependent vasorelaxation induced by L-carnitine in isolated aorta from normotensive and hypertensive rats. J. Pharm. Pharmacol. 2002;54(10):1423–1427. doi: 10.1211/002235702760345536
19. CHekman IS, Gorchakova NA, Francuzova SB, Nagornaya EA. Metabolitnye i metabolitotropnye preparaty v sisteme kardio- i organoprotekcii [Metabolitic and metabotropotropic drugs in the system of cardio and organoprotection]. Kyiv: Polihraf plius, 2009. 155 p.
20. Filippov MM, Davidenko DN. Fiziologicheskie mekhanizmy razvitiya i kompensacii sostoyaniya gipoksii v processe adaptacii k myshechnoj deyatel'nosti [Physiological mechanisms of development and compensation of hypoxia in the process of adaptation to muscular activity]. St. Petersburg. Kiev: BPA, 2010. 260 p.
21. Sosnowskiy VV,. Pastukhova VA. [Adaptation of human organism to hypoxia]. Cherkasy university bulletin: biological sciences series 2017;1:97-106.
22. Corrado D, Drezner J, Basso C, Pelliccia A, Thiene G. Strategies for the prevention of sudden cardiac death during sports. Eur. J. Cardiovasc. Prev. Rehabil. 2011;18: 197–208.
23. Sokolova NI, Vladimirova NМ, Теmkina ОЕ, Vasilenko YN. Metabolic therapy impact on athletes’ functional state. Novosti meditsiny i farmatsiyi. 2005;9(169):6–7.
24. Gunina L, Bezuglaya V, Petrik P, CHerednichenko O, Olishevskij S, Gumenyuk R. [Influence of the "Cardonat" metabolic polypepter on the tolerance of skilled athletes to physical activity]. Nauka v olimpijskom sporte. 2013;1:56-60.
Published
2020-10-04
How to Cite
V. Klapchuk, V. Bezugla, & Yu. Vinnichuk. (2020). ASSESSMENT OF CARDONAT EFFICIENCY IN CARDIOMYOPATHY TREATMENT AFTER PHYSICAL OVERLOAD IN ATHLETES. Eastern Ukrainian Medical Journal, 6(4), 396–408. Retrieved from https://eumj.med.sumdu.edu.ua/index.php/journal/article/view/107